CXCL12 and chronic myelogenous leukemia, BCR-ABL1 positive: CXCL12 conferred the resistance to adriamycin on CML cells by augmenting their CXCR4 expression and CXCR4 siRNA treatment can partially reduce adriamycin resistance [79].